Report cover image

Melinta Therapeutics LLC - Strategic SWOT Analysis Review

Publisher GlobalData
Published Feb 27, 2026
Length 31 Pages
SKU # GBDT20940132

Description

Melinta Therapeutics LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Melinta Therapeutics LLC (Melinta), a subsidiary of CorMedix Inc, is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. The company's marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin and minocycline. Melinta's products and pipeline candidates are built on a ribosome platform licensed from Yale University. Melinta is headquartered in Parsippany, New Jersey, the US.

Melinta Therapeutics LLC Key Recent Developments

Jan 08,2026: CorMedix Therapeutics Reports Preliminary Q4 and Full-Year 2025 Results and Business Updates
Dec 18,2025: CorMedix Therapeutics Announces Positive Real-World Evidence Results for DefenCath
Sep 29,2025: CorMedix Completes Enrollment in Phase III Clinical Trial for REZZAYO

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.

Table of Contents

31 Pages
Section 1 - About the Company
Melinta Therapeutics LLC - Key Facts
Melinta Therapeutics LLC - Key Employees
Melinta Therapeutics LLC - Key Employee Biographies
Melinta Therapeutics LLC - Major Products and Services
Melinta Therapeutics LLC - History
Melinta Therapeutics LLC - Company Statement
Melinta Therapeutics LLC - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Melinta Therapeutics LLC - Business Description
R&D Overview
Melinta Therapeutics LLC - Corporate Strategy
Melinta Therapeutics LLC - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics LLC - Strengths
Melinta Therapeutics LLC - Weaknesses
Melinta Therapeutics LLC - Opportunities
Melinta Therapeutics LLC - Threats
Melinta Therapeutics LLC - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Melinta Therapeutics LLC, Recent Deals Summary
Section 4 – Company’s Recent Developments
Jan 08, 2026: CorMedix Therapeutics Reports Preliminary Q4 and Full-Year 2025 Results and Business Updates
Dec 18, 2025: CorMedix Therapeutics Announces Positive Real-World Evidence Results for DefenCath
Sep 29, 2025: CorMedix Completes Enrollment in Phase III Clinical Trial for REZZAYO
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Melinta Therapeutics LLC, Key Facts
Melinta Therapeutics LLC, Key Employees
Melinta Therapeutics LLC, Key Employee Biographies
Melinta Therapeutics LLC, Major Products and Services
Melinta Therapeutics LLC, History
Melinta Therapeutics LLC, Subsidiaries
Melinta Therapeutics LLC, Key Competitors
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Melinta Therapeutics LLC, Recent Deals Summary
List of Figures
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Melinta Therapeutics LLC, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us